CME: Major Depressive Disorders (MDD): Best Practice And The Role Of Novel Therapies
ACCREDITATION EXPIRED: April 12, 2018
Activity Description / Statement of Need:
In this online CME self-learning program:
Major depressive disorder (MDD) is presently and has been a persistent major public health burden for several decades.1-5 Based on the National Comorbidity Survey data using the Composite International Diagnostic Interview, the estimated risk of MDD over any given 12-month period is 6.6% (13.1 – 14.2 million U.S. adults), with an estimated lifetime risk of 16.2% (32.6 – 35.1 millions US adults).1,2 Another estimate, from a recent wave of the National Health and Nutrition Examination Survey, indicates that 17.53% of men and 25.52% of women across all ages report having experienced depressive symptoms in the past.4 Unfortunately, 58.8% of adults with symptoms classified as moderate and 36.9% of adults with symptoms classified as severe neither saw mental health professional nor received pharmacological treatment,4 suggesting a gap between present and optimal treatment of MDD.
This program has been designed to bring healthcare professionals’ knowledge up to date with the currently best and recommended practices in treating MDD.
Agenda:
|
Introduction, disclosures |
|
Epidemiology and risk factors for major depressive disorder
|
|
Symptomology and diagnosis of MDD [Learning objective #s 1, 2, & 3]
|
|
Treatment in patients with MDD [Learning objective #s 3, 4, & 5]
|
|
Barrier to Optimal Care in Patients with Major Depressive Disorder [Objective #6]
|
|
Summary, conclusion, and best practice recap |
Target Audience:
Healthcare professionals specializing in: psychiatry, primary care, and those who otherwise commonly care for patients with MDD or related psychiatric diseases.
This program is supported by an educational grant from Alkermes.
Release Date: April 12, 2016 -- Expiration Date: April 12, 2018
Faculty: Charles DeBattista, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Recognize and provide optimal care for patients with MDD including regular assessment of symptom resolution, treatment adherence, and tolerability concerns.
- Describe the impact of acute and residual symptoms of cognitive dysfunction in depression on patient function, quality of life, relapse risk and long-term outcomes
- Identify patients who might benefit from new pharmacologic treatment options (e.g., those with inadequate response to therapy or tolerability concerns).
- Effectively and safely integrate care changes into the MDD treatment regimen as needed to achieve long-term treatment success.
- Identify newer pharmacotherapies and medical device treatment MDD and contrast them with therapies to determine their place.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Charles De Battista, MD discloses that he has received grant funding and / or is a consultant for Genentech, Pfizer, Assurex, Brain Resources, and St. Jude.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Alkermes.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Best Practices and Advances in Treatment Strategies in Bipolar Disorder Pharmacotherapy
Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices
Schizophrenia: Updates from the American Psychiatric Association Annual Meeting (APA) 2017